<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04616261</url>
  </required_header>
  <id_info>
    <org_study_id>FOREX</org_study_id>
    <nct_id>NCT04616261</nct_id>
  </id_info>
  <brief_title>Beta2-adrenergic System and Training</brief_title>
  <official_title>Trainability of the beta2-adrenergic System With Respect to Performance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project aims to examine the trainability of the beta2-adrenergic system with respect to&#xD;
      the individual performance response&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 10, 2020</start_date>
  <completion_date type="Anticipated">November 10, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 10, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sprint performance</measure>
    <time_frame>½ hour after administration of formoterol or placebo</time_frame>
    <description>Change in power output during maximal cycling in response to formoterol</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cycling endurance performance</measure>
    <time_frame>½ hour after administration of formoterol or placebo</time_frame>
    <description>Change in 4-min time trial performance in response to formoterol</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>SET-HIGH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High volume speed endurance training</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SET-LOW</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low volume speed endurance training</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Training</intervention_name>
    <description>6 weeks of training</description>
    <arm_group_label>SET-HIGH</arm_group_label>
    <arm_group_label>SET-LOW</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formoterol</intervention_name>
    <description>inhalation of 54 microg formoterol</description>
    <arm_group_label>SET-HIGH</arm_group_label>
    <arm_group_label>SET-LOW</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>inhalation of placebo</description>
    <arm_group_label>SET-HIGH</arm_group_label>
    <arm_group_label>SET-LOW</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 to 45 years of age&#xD;
&#xD;
          -  Trained individuals with a maximal oxygen uptake above 55 ml/min/kg&#xD;
&#xD;
          -  Body mass index lower than 26&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergy towards study drug&#xD;
&#xD;
          -  Unacceptable side effects to the study drug&#xD;
&#xD;
          -  Chronic disease deemed by the MD to interfere with the study&#xD;
&#xD;
          -  Smoking&#xD;
&#xD;
          -  Use of prescription medicine&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 29, 2020</study_first_submitted>
  <study_first_submitted_qc>November 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2020</study_first_posted>
  <last_update_submitted>November 3, 2020</last_update_submitted>
  <last_update_submitted_qc>November 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Copenhagen</investigator_affiliation>
    <investigator_full_name>Morten Hostrup, PhD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

